Antares Pharma, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Antares Pharma, Inc.
With the US filing of its non-sedative sleeping pill now imminent, the Swiss biotech is also adding to its war chest to advance Phase III drugs aprocitentan, clazosentan and lucerastat.
Following a strategic review, AMAG goes to Covis. Vincera goes public in merger with blank check company, has pending cancer deal with Bayer.
Danish firm picks up portfolio and manufacturing sites, along with around 600 employees.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.
- Medical Devices
- Specialty Pharmaceuticals
- Controlled Release
- Topical Delivery
- Other Names / Subsidiaries
- Medi-Ject Corporation